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Abstract 
Background 
Epidemiology and animal models suggest that dietary monosodium glutamate (MSG) may 
contribute to the onset of obesity and the metabolic syndrome. 
Methods 
Families (n = 324) from a rural area of Thailand were selected and provided MSG as the sole 
source for the use in meal preparation for 10 days. Three hundred forty-nine subjects aged 
35–55 years completed the study and were evaluated for energy and nutrient intake, physical 
activity, and tobacco smoking. The prevalence of overweight and obesity (BMI ≥ 25 kg/m2), 
insulin resistance (HOMA-IR >3), and the metabolic syndrome (ATP III criteria) were 
evaluated according to the daily MSG intake. 
Results 
The prevalence of the metabolic syndrome was significantly higher in the tertile with the 
highest MSG intake. Further, every 1 g increase in MSG intake significantly increased the 
risk of having the metabolic syndrome (odds ratio 1.14, 95% confidence interval-CI- 1.12 - 
1.28) or being overweight (odds ratio 1.16, 95% CI 1.04 - 1.29), independent of the total 
energy intake and the level of physical activity. 
Conclusion 
Higher amounts of individual MSG consumption are associated with the risk of having the 
metabolic syndrome and being overweight independent of other major determinants. 
Keywords 
Functional food, Obesity, Metabolic syndrome, Thailand 
Background 
The metabolic syndrome is a cluster of cardiovascular risk factors including major risk 
factors are abdominal obesity and insulin resistance. Moreover, other risk factors have been 
proposed including physical inactivity, aging, smoking, and carbohydrate and fat dietary 
intake [1]. The incidence and prevalence of the metabolic syndrome are rapidly growing 
causing a significant burden for health systems worldwide [2]. 
Monosodium glutamate (MSG) is a flavor enhancer largely used in the food industry with 
individual consumption steadily increasing worldwide. Recent cross-sectional and 
longitudinal studies in healthy Chinese subjects correlated MSG intake with an increased risk 
of being overweight irrespective of the total calorie intake and physical activity [3,4]. Animal 
models support a causative association between obesity and neonatal or maternal 
administration of high doses of MSG [5], possibly acting on immature neurological 
mechanisms that regulate food intake and energy expenditure [6]. Similarly, an elevated 
dietary MSG intake in rodent models leads to increased in serum triglyceride [7], fasting 
glucose [8], and insulin levels [7,8], the metabolic disorder markers. 
To determine whether MSG is associated with the metabolic syndrome in humans, we 
conducted a study in the general adult population of a rural area of Thailand and report herein 
that the daily intake significantly correlates with the prevalence of the syndrome, irrespective 
of physical activity and calorie intake. 
Methods 
Participants 
The study included families from six villages within the Khon Kaen province. The chosen 
villages included 880 families with a total of 4472 subjects that were screened through the 
involvement of health volunteers between October 2009 and April 2010. Following this first 
screening, we identified 324 families with 487 participants fulfilling the inclusion criteria, i.e. 
(i) preparing meals for family members at least two times each day, (ii) reporting the regular 
use of MSG as food additive, (iii) including a member between the ages of 35–55 years, and 
(iv) agreeing to take part in the study. Family members (n = 1–3 per family) of both sexes 
within the target age range were trained by health volunteer and research personnel to 
maintain a detailed dietary record for the duration of the study. Participants had their medical 
history taken including physical activity, tobacco smoking, family history of diabetes mellitus 
and ongoing medical treatments. We excluded participants who had chronic pulmonary, 
heart, kidney, liver, or psychiatric condition, established diabetes, active neoplasia or were 
receiving any prescription medication at the time of screening. The use of non steroidal anti-
inflammatory medications or acetaminophen less than once a week was allowed. Participants 
were provided with 250 g of MSG in a plastic box to be used as the sole source of MSG for 
food preparation for 10 days. The amount utilized was registered at the end of this period 
(based on the returned box) and then divided by the number of subjects over 10 years of age 
in the household to estimate the individual use expressed as g/person/day. The study design 
and procedures were approved by the Human Ethical Committee of Khon Kaen University, 
Thailand, followed the ethical guidelines of the most recent Declaration of Helsinki 
(Edinburgh, 2000), and all participants gave their written consent prior to enrollment. 
Medical history 
Calorie intake was calculated in randomly selected three-day periods in different villages 
using a 24-hour recall diary for which participants had been previously trained by health 
volunteers. All foods, drinks, and supplements were included using cups and spoons as units 
for clarity purposes. Diet data were coded and analyzed using the INMUCAL program 
version 7, software package developed by the Institute of Nutrition, Mahidol University, to 
determine daily energy and nutrient intakes [9]. This software provides an accurate 
measurement of the dietary intake of participants as part of each meal and subdivided into 
energy (Kcal), carbohydrate (g), lipid (g) and protein (g) contents to be used for statistical 
analysis. Participants were asked to indicate their levels of physical activity which was 
arrayed into sedentary, moderately active, and vigorously active. The modified version of the 
International Physical Activity Questionnaire (IPAQ) [10] was administered at a random date 
of the 10-day MSG supplementation period. The questionnaire is divided into 3 items 
assessing (i) the physical activity related to household chores such as cooking, cleaning and 
gardening, (ii) exercise and sports, and (iii) work-related activity. The physical activity levels 
(PAL) were subsequently calculated according to the 2001 FAO/WHO/UNU expert 
consultation [11]. All participants were asked about tobacco smoking and family history of 
diabetes as potentially confounding factors. 
Physical examination and bloodwork 
Participants who completed MSG assessment and lifestyle covariates underwent a physical 
examination and blood collection for biochemical analyses. Blood pressure was measured in 
the sitting position after resting for a few minutes using an automatic sphygmomanometer. 
The waist circumference was measured at a level midway between the lower rib margin and 
the iliac crest while the participants stood. Body weight was measured in light indoor 
clothing without shoes and height measured using a secured ruler; the body mass index 
(BMI) was calculated accordingly. Following overnight fasting, a venous blood sample was 
obtained to determine the concentrations of triglyceride, total and HDL cholesterol, glucose, 
and insulin using routine laboratory methods. The Homeostasis Model Assessment for insulin 
resistance (HOMA-IR) was calculated using the formula: [fasting serum insulin (μU/ml) × 
fasting plasma glucose (mmol/L)]/22.5 [12]. Insulin resistance was defined as HOMA-IR >3. 
Overweight was defined as BMI ≥25 kg/m2 according to the WHO criteria [13]. The 
diagnosis of metabolic syndrome was made according to the National Cholesterol Education 
Program Adult Treatment Panel III (ATP III) (2004) criteria [1]. Three or more of the five 
following criteria characterized the metabolic syndrome: abdominal obesity, waist 
circumference ≥90 cm for men and ≥80 cm for women; systolic blood pressure ≥130 mmHg 
and diastolic blood pressure ≥85 mmHg; fasting plasma glucose >100 mg/dL; serum 
triglyceride ≥150 mg/dL; HDL cholesterol <40 mg/dL) for men and <50 mg/dL for women. 
Statistical analysis 
For the purpose of statistical analysis, participants were subdivided into tertiles of MSG 
intake expressed as median (interquartile range, IQR). Baseline characteristics were first 
assessed according to tertiles of MSG consumption. Continuous variables are reported as 
medians and IQR (i.e., values corresponding to the 25
th
 and the 75
th
 percentiles). Differences 
between tertiles were tested for statistical significance by chi-square test for categorical 
variables and by Kruskal-Wallis test for continuous variables. The Mantel-Haenszel chi-
square test was utilized to examine the linear trend of prevalence of insulin resistance, 
overweight, and metabolic syndrome, and its components across tertiles of MSG intake. The 
association of MSG consumption with metabolic syndrome was assessed by binary logistic 
regression analysis adjusting for predefined sets of independent variables such as sex, age, 
family history of diabetes mellitus, smoking status, physical activity levels and total energy 
intake. All analyses were two-tailed and performed using SPSS 16.0 for Windows (IBM 
Company, Chicago, IL). P values <0.05 were considered as statistically significant. 
Results 
We obtained complete information from 349/487 (72%) participants. The remaining 138 
(28%) participants dropped out of the study by not attending physical examination and blood 
collection (n = 113), providing insufficient questionnaire data (n = 11) and/or blood amount 
(n = 13). An average MSG intake of 4.0 ± 2.2 (range 0.4–14.0) g/day was recorded with a 
distribution skewed towards lower values. When divided into 3 groups, the median MSG 
intake for each tertile was 1.9 g (IQR 1.5–2.3) for tertile 1, 3.6 g (IQR 3.2–4.2) for tertile 2, 
and 6.0 g (IQR 5.2–7.4) g/day for tertile 3 (Table 1). There were no significant differences in 
sex distribution, family history of diabetes, smoking status, physical activity, and daily 
energy intake among participants in the different tertiles, with the exception of age (P = 
0.044). The majority of participants was classified as non-smokers (256/349, 73%) and had a 
vigorously active lifestyle (231/349, 66%). Insulin resistance was diagnosed in 96/349, 28% 
of participants with 130/349, 37% were classified as overweight, and 83/349, 24% fulfilling 
the metabolic syndrome diagnostic criteria. When single criteria of metabolic syndrome were 
analyzed, the overall prevalence of enhanced waist circumference was 124/349, 36%, 
hyperglycemia 142/349, 41%, hypertriglyceridemia 145/349, 42%, low HDL cholesterol 
112/349, 32%, and hypertension 77/349, 22%. There were no differences in levels of fasting 
blood glucose, triglycerides, HDL cholesterol, blood pressure, waist circumference, and BMI 
among tertiles of MSG intake, with the exception of insulin plasma levels (P = 0.041). A 
significant trend towards increasing prevalence across the different tertiles of MSG intake 
was observed for the prevalence of insulin resistance (P = 0.028), overweight (P = 0.021), and 
metabolic syndrome (P = 0.014). The prevalence of hyperglycemia, elevated blood pressure, 
and enhanced waist circumference apparently increased towards the highest tertile of MSG 
intake but differences did not reach a statistical significance. 
Table 1 Main participant characteristics according to Tertiles of MSG intake 
Characteristics Total (n=349) 
MSG intake 
P 
Tertile 1 ( n=116)  Tertile 2 (n=117) Tertile 3 (n=116) 
Median MSG intake (g/day) 3.6 (2.3-5.25) 1.9 (1.5-2.3) 3.6 (3.2-4.2) 6.0 (5.2-7.4)   
Women 217 (62.2%) 72 (62.1%) 72 (61.5%) 73 (62.9%) 0.976
 2 
Age (years) 46.0 (40.0-50.0)
  44.0 (40.0-49.0) 1 46.0 (40.0-51.0) 47.0 (42.0-50.0) 0.044 2 
Family history of diabetes 102 (29.2%) 36 (31.0%) 31 (26.5%) 35 (30.2%) 0.721
 2 
Smoking status 
     
     Never smoked 256 (73.3%) 84 (72.4%) 83 (71.0%) 89 (76.7%) 0.264 2 
     Former 10 (2.9%) 3 (2.6 %) 4 (3.4%) 3 (2.6%) 
 
     Current  83 (23.8%) 29 (25.0%) 30 (25.6%) 24 (20.7%) 
 
Physical activity / lifestyle 
     
     Sedentary  48 (13.7%) 14 (12.1%) 17 (14.5%) 17 (14.7%) 0.721 2 
     Moderately active  70 (20.1%) 27 (23.3%) 19 (16.3%) 24 (20.7%) 
 
     Vigorously active  231 (66.2%) 75 (64.6%) 81 (69.2%) 75 (64.6%) 
 
Daily nutrient intake 
     
     Energy intake (Kcal) 2,032 (1,747-2,397)  2,051 (1,758-2,381) 1 2,029 (1,687-2,380) 2,017 (1,765-2,413) 0.905 2 
     Carbohydrate (g) 333.8 (275.8-412.3)  342.2 (280.9-413.8) 1 328.1 (260.2-422.7) 341.2 (280.8-407.2) 0.569 2 
     Fat (g) 33.1 (25.9-43.4)  34.1 (26.1-42.1) 1 32.8 (26.3-44.2) 31.7 (24.5-43.7) 0.739 2 
     Total protein (g) 81.1 (68.8-96.9)  82.5 (70.7-97.6) 1 81.1 (67.6-93.0) 70.4 (67.5-95.3) 0.437 2 
Metabolic parameters 
     
     HOMA-IR 2.3 (1.7-3.3)  2.1 (1.6-2.8) 1 2.3 (1.6-3.3) 2.4 (1.9-3.5) 0.028 2 
 % HOMA-IR >3 96 (27.5%) 24 (20.7%) 33 (28.2%) 39 (33.6%) 0.028 3 
     Insulin (ng/dL) 9.1 (7.0-13.2)  8.5 (6.6-12.0) 1 9.0 (6.8-13.0) 9.9 (7.5-14.1) 0.041 2 
     Glucose (mg/dL) 97.0 (92.0-104.0)  97.0 (92.0-104.0) 1 98.0 (91.5-103.5) 99.0 (92.0-105.0) 0.647 2 
% glucose >100 mg/dL 142 (40.7%) 40 (30.7%) 48 (40.9%) 54 (43.0%) 0.062 3 
     Triglyceride (mg/dL)  137.7 (104.1-191.1)  139.1 (95.1-197.4) 1 139.0 (104.0-203.1) 134.2 (109.7-187.8) 0.729 2 
% Triglycerides ≥150 mg/dL 145 (41.5%) 48 (41.4%) 49 (41.9%) 48 (41.4%) 0.996 3 
     HDL-C (mg/dL) 53.0 (44.0-63.0)  51.0 (41.0-62.8) 1 53.0 (45.0-65.0) 53.5 (45.0-64.0) 0.407 2 
 % HDL-C <50 mg/dL F, <40 mg/dL M 112 (32.1%) 44 (37.9%) 34 (29.1%) 34 (29.3%) 0.160 3 
     SBP (mmHg) 124.0 (116.0-136.0)  124.0 (116.0-133.8) 1 125.0 (116.0-135.5) 123.0 (115.3-136.8) 0.910 2 
     DBP (mmHg) 79.0 (72.5-86.0)  78.0 (73.0-85.0) 1 80.0 (75.0-86.0) 80.0 (71.3-87.0) 0.503 2 
% SBP ≥ 130 and DBP ≥ 85 mmHg 77 (22.1%) 21 (18.1%) 27 (23.1%) 29 (25.0%) 0.206 3 
     Waist circumference (cm) 79.0 (72.0-86.0)  78.5 (72.6-85.0) 1 77.0 (71.9-86.0) 81.0 (73.0-88.0) 0.207 2 
%WC >80cm F, >90cm M 124 (35.5%) 39 (33.6%) 35 (29.9%) 50 (43.1%) 0.132 3 
     BMI (kg/m2) 23.7 (21.2-26.8)  23.5 (21.3-26.4) 1 23.1 (20.9-26.8) 24.6 (21.3-27.3) 0.308 2 
           % BMI  ≥ 25 kg/m2 130 (37.2%) 36 (31.0%) 41 (35.0%) 53 (45.7 %) 0.021 3 
Metabolic syndrome (ATP III criteria) 83 (23.8%) 20 (17.2%) 27 (23.1%) 36 (31.0%) 0.014
 3 
1
 Continuous variables are expressed as median (interquartile range). 
2
 P value comparing the characteristics of participants across tertiles of MSG intake using chi-
square test for categorical variables and by Kruskal-Wallis test for continuous variables. 
3
 P values comparing prevalence of each metabolic feature across tertiles of MSG intake using the 
Mantel-Haenszel chi-square test for trend. 
HDL-C high density lipoprotein cholesterol, F female, M male, SBP systolic blood pressure DBP 
diastolic blood pressure, WC Waist circumference, BMI body mass index. 
The binary logistic regression analysis with potentially confounding factors is illustrated in 
Table 2. MSG intake was independently associated with having the metabolic syndrome after 
adjustment for potential confounding factors such as calories intake, age, sex, physical 
activity level, smoking level, and history of diabetes. Further, every 1-g increase in MSG 
intake slightly but significantly increased the odds of metabolic syndrome (odds ratio 1.14, 
95% CI 1.12–1.28) and overweight (odds ratio 1.16, 95% CI 1.04–1.29) increased 
significantly. 
Table 2 Odds ratio and 95% CI for MSG intake associated with increased risks of 
insulin resistance, overweight, and metabolic syndrome 
  Number of participants OR (95%CI) P  
Insulin resistance (HOMA-IR > 3) 349 1.05(0.94-1.18)* 0.371 
Overweight (BMI ≥ 25 kg/m2) 349 1.16(1.04-1.29)* 0.007 
Metabolic syndrome (ATPIII criteria) 349 1.14(1.12-1.28)* 0.025 
* adjusted for sex, age, physical activity level, smoking level, history of diabetes and calories 
intake 
Discussion 
The present study reports a significant association between the risk of the metabolic 
syndrome and MSG daily consumption in a rural area of Thailand where people cook their 
own meals with the typical eating habit of sharing food among family members. Importantly, 
the association is independent of major confounding factors such as age, sex, smoking, family 
history, physical activity, or calorie intake. This unique context allowed the measurement of 
MSG consumption for 10 days to be more accurate than the use of questionnaires. 
The metabolic syndrome is currently considered as the most prominent risk factor for 
cardiovascular diseases worldwide. Data from the Third National Health and Nutrition 
Examination Survey (NHANES III) on 8,814 men and women suggest that 20 to 30% of 
adults in developed countries meet the syndrome criteria [14]. In addition to an elevated 
calorie intake [15], specific dietary factors have been linked with the incidence of the 
syndrome with conflicting results [16]. MSG is a common flavor enhancer and naturally 
occurring amino acid utilized in increasing amounts in food industry and preparation. Despite 
its optimal safety profile [17], a large cross-sectional study revealed that MSG consumption 
is related to a higher increase in blood pressure [18]. Moreover, MSG has been linked with 
obesity, type II diabetes, and the metabolic syndrome as its intake in healthy Chinese adults 
correlates with the resulting increase in body mass index regardless of energy intake [3,4]. 
We found a significant trend for increasing insulin levels and prevalence of insulin resistance 
across tertiles of MSG intake. However, the change did not alter the glucose homeostasis 
significantly as fasting blood sugar did not differ among different levels of MSG intake. This 
is in agreement with the observation that the administration of MSG to fasting human 
subjects increases insulin levels without altering glucose concentration and glucose tolerance 
[19]. While glutamate is known to stimulate insulin secretion via glutamate, the optimal 
glucose regulation in healthy volunteer may overcome the intermittent rising of insulin level 
[19,20]. 
Further evidence of a link between MSG and the metabolic disorders is obtained from animal 
models. High doses of MSG injected in rodents during the neonatal period lead to the 
development of glucose intolerance, insulin resistance [21], and obesity [5] along with 
adipose tissue hypertrophy, hyperinsulinemia, hyperglycemia, hyperleptinemia, and 
decreased insulin stimulated glucose transport in adipocytes and muscle [22-24]. These 
changes in glucose metabolism and insulin resistance were not observed when MSG was 
administered to adult animals, thus suggesting that the endocrine regulation in these animals 
is very sensitive to MSG during the early postnatal period [23]. The metabolic disturbances 
found in this present study might be the sum of exposure during early life via the maternal 
diet including in their later life [25]. 
MSG is a common additive used in Thai cuisine and we observed an average MSG intake of 
4.0 g/day which was over two times higher than an older survey of Thai adults [26]. The 
MSG intake in this study was similar to that recent report in Chinese population (3.8 g/day) 
by the Jiangsu Nutrition Study [27]. However, our recorded MSG intake was 12 and 2 times 
higher compared to that of the two Chinese population nutritional surveys, i.e. the 
INTERMAP study [3] and the China Health and Nutrition Survey (CHNS) [4], respectively. 
While we can only speculate on the impact of different eating habits, our measurement of 
MSG consumption based on common cooking habits in a limited area with uniform dietary 
and physical activity regimens. Further, to be included in the present study families had to 
prepare their meals twice a day thus limiting the impact of commercially available food. 
Lastly, inhabitants of Thai rural areas rarely eat restaurant food compared to urban areas, thus 
minimizing this potential confounding factor. 
Additional observations strengthen our hypothesis. First, we should note that daily energy 
intake and physical activity levels are not significantly different among tertiles of MSG 
consumption, possibly based on the fact that 66% of participants are agricultural workers 
with a vigorously active lifestyle. Second, the prevalence rates of hypertriglyceridemia and 
low HDL cholesterol levels are not associated with MSG intake, while the overall prevalence 
of hypertriglyceridemia is similar to data from Thai adults in rural areas [28]. Our data 
demonstrate the significant trends of insulin resistance, overweight, and metabolic syndrome 
towards levels of MSG intake. However, after adjusting for the confounding factors such as 
sex, age, calories intake, physical activity, smoking status, and history of diabetes, the MSG 
consumption does not significantly increase risk of insulin resistance. Since there were no 
differences in glucose level and energy intake in different tertiles of MSG consumption, the 
metabolic syndrome associated with MSG intake is probably not due to the energy intake-
induced obesity leading to insulin resistance. The finding of MSG consumption significantly 
correlated with BMI in our study agreed with the two studies in Chinese population, 
INTERMAP and CHNS [3,4], through a mechanism possibly mediated by white adipose 
tissue deposition, as suggested in animal models [7,23,29]. MSG may enhance shifting the 
dietary glucose towards lipid synthesis [23], increasing the rate of lipogenesis [29] and 
activating gene expression of enzymes involved in lipid biosynthesis and storage in adipose 
tissue [7]. 
Our results demonstrate that MSG intake is associated with the risk of having the metabolic 
syndrome. A longitudinal study with a larger sample size is needed for confirmation the 
contribution effect of MSG on the development of metabolic syndrome, a rising global 
metabolic emergency. 
Conclusions 
The present study supports that an elevated dietary MSG consumption is significantly 
associated with having the metabolic syndrome and being overweight in a Thai rural 
population. We may surmise that a person with a daily consumption of MSG exceeding 5 g 
should be considered at risk for metabolic disorder. 
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